The effects of the GABA agonist, baclofen, on sleep and breathing

A.J. Finnmore, M. Roebuck, D. Sajkov, R.D. McEvoy


ABSTRACT: The gamma aminobutyric acid (GABA)-B agonist, baclofen, is a centrally-acting, anti-spasmodic agent and muscle relaxant used in spinal cord lesions, multiple sclerosis and other neurological disorders. In a previous pilot study of quadriplegic patients, 75% of whom were treated with baclofen, we found a high prevalence of sleep-disordered breathing. Because of the depressant effects of GABA on the central nervous system, we hypothesized that baclofen might aggravate sleep-disordered breathing in susceptible individuals by depressing central ventilatory drive, increasing upper airway obstruction and/or increasing the arousal threshold to apnoea.

We therefore conducted a double-blind, placebo-controlled, cross-over study of baclofen 25 mg, administered before sleep in 10 snorers with mild sleep-disordered breathing (respiratory disturbance index <30 events per sleep hour). Each subject underwent two standard polysomnographic assessments, one week apart.

Total sleep time was significantly prolonged by baclofen (placebo 356±9.9 min; baclofen 386±9.9 min). Both nonrapid eye movement(REM) and REM sleep duration were increased (nonREM: placebo 295±6.8 min; baclofen 311±8.9 min; REM: placebo 61±7.5 min; baclofen 76±9.0 min). Time spent awake after sleep onset was reduced after baclofen (placebo 71±10.3 min; baclofen 51±9.7 min). There was a slight reduction in mean overnight oxygen saturation (placebo 95.2±0.5%; baclofen 94.4±0.7%). The frequency of apnoeas plus hypopnoeas (respiratory disturbance index (RDI)) did not change significantly (placebo 9±1.8 events·h⁻¹; baclofen 13±3.4 events·h⁻¹).

We conclude that a single, therapeutic dose of baclofen alters sleep architecture and produces a small reduction in mean sleep oxygen saturation, but does not significantly increase sleep-disordered breathing.


Baclofen is a centrally-acting gamma aminobutyric acid (GABA)-B agonist with muscle relaxant and anti-spasmodic properties. It is widely used in the treatment of painful spasms in patients with spinal cord lesions, multiple sclerosis and other neurological disorders [1]. It has also been used experimentally to treat periodic limb movements during sleep [2]. GABA is a neurotransmitter with mainly inhibitory effects in the central nervous system and appears to decrease central ventilatory drive. It has been shown to decrease ventilation and ventilatory responsiveness to hypercapnia in experimental animals [3–5], and is a putative mediator of hypoxic ventilatory depression [6].

In a preliminary study, we found a high prevalence of significant nocturnal hypoxia in quadriplegic patients [7]. Subsequent polysomnographic studies of 40 quadriplegics from the same population (unpublished data) have shown a high prevalence of obstructive sleep apnoea (OSA); which concurs with the results of preliminary studies reported by other groups [8–10]. We conducted a survey of quadriplegic patients in South Australia, and found that 75% were treated with baclofen at an average evening dose of 30 mg (range 10–50 mg); whereas, other anti-spasmodic agents were used less frequently (diazepam, 5–10 mg nocte in 58%, and dantrolene in 28%). It seemed important, therefore, to objectively assess the effects of baclofen on breathing during sleep.

We hypothesized that the adverse effects of baclofen on respiratory control would be most evident during sleep, especially in patients with a pre-existing tendency to sleep-disordered breathing. Because of its muscle relaxant properties, baclofen could increase the tendency to upper airway collapse during sleep and increase obstructive apnoeas (e.g. in snorers); whilst its depressant effect on respiratory drive might lead to central apnoeas or sleep hypoventilation. We report a double-blind, placebo-controlled study of baclofen in 10 otherwise healthy snorers with mild sleep-disordered breathing.
Methods

Subjects

Ten volunteers (nine males and one female) were recruited from our Sleep Clinic population. Each of the volunteers was a chronic snorer and had been referred for polysomnography for the investigation of obstructive sleep apnoea (OSA). For inclusion in the study, they had to meet the following criteria: 1) apnoea index (AI) of $\leq 5$ apnoeas·h$^{-1}$ of sleep; 2) respiratory disturbance index (RDI; apnoeas + hypopnoeas) 5–30 events·h$^{-1}$ of sleep; and 3) nadir $O_2$ saturation greater than 70%. We deliberately chose patients who had mild OSA to reduce the risk of a serious exacerbation following baclofen, but at the same time we postulated that this would allow any adverse effect of the drug to be detected and quantified. All subjects were informed of the purpose of the study and gave informed consent by signing a consent form that had previously been approved by the Research and Ethics Committee of the Repatriation General Hospital, Daw Park.

Subjects were asked to refrain from the use of alcohol or caffeine for 8 h prior to testing and from smoking for at least 1 h before and during each sleep study. The subjects ranged 26–70 yrs in age and had no concomitant diseases, with the exception of controlled hypertension. They were asked to keep their normal sleep-wake schedule for at least 3 days before the sleep study. Other exclusion criteria were acute respiratory tract infection, or concurrent treatment with sedatives or muscle relaxants.

Anthropometric and relevant diagnostic sleep study results for the selected subjects are shown in table 1.

Experimental Design

A dose of 25 mg baclofen (Lioresal, Ciba Geigy) or placebo was administered 2 h before the start of the sleep study. The kinetics of baclofen are such that by 10 h after ingestion serum levels are clinically insignificant. In healthy adults, the half-life ($T_{1/2}$) is 3.8 h [11]. Repeated dosing on an 8 hourly schedule leads to only a minor rise in peak serum levels [12]. We considered, therefore, that use of a single nocturnal dose equal in size to the average dose used by our quadriplegic patients was clinically relevant, and should have enabled a pharmacological effect on sleep and breathing to be demonstrated if such an effect existed.

Each subject had adapted to the sleep laboratory during the diagnostic sleep study. For the present study they underwent two additional polysomnographic measurements one week apart. The order of administration of active drug or placebo (25 mg lactose) was random and double-blinded. Drug and placebo could not be distinguished in appearance, both being placed inside an opaque gelatine capsule.

Protocol

Sleep recordings were made using a computerized data acquisition system (Sleepwatch, Compumedics, Melbourne, Australia). Monitored variables included: electroencephalogram (EEG) (C3/A2 or C4/A1), oronasal airflow (Compumedics thermistor), chin electromyogram (EMG), electrocardiogram (2 leads ECG), pulse oximetry oxygen saturation ($SpO_2$; Criticare 504 pulse oximeter, Waukesha, Wi, USA), leg movements (movement sensors, Compumedics) and body position (mercury switch position sensor, Compumedics). Respiratory movements of the chest and abdomen were monitored with an impedance plethysmograph (Vitalog, Ca, USA). A high digital sampling speed was used: 125 Hz for EEG and ECG; 50 Hz for electro-oculogram (EOG), ECG and leg movements; 10 Hz for respiratory movements and nasal thermometer; and 5 Hz for $SpO_2$. Data were displayed on a high resolution 20 inch monitor (NEC multisync 6FG, Tokyo, Japan). Twenty seconds of real time data were displayed per screen for visual scoring of sleep stages, and 5 min per screen for visual scoring of respiratory events. Automatic analysis was used only to compute

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age yrs</th>
<th>BMI</th>
<th>Sex</th>
<th>Minimum $SpO_2$%</th>
<th>RDI (total) events·h$^{-1}$</th>
<th>RDI (REM) events·h$^{-1}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>26</td>
<td>32</td>
<td>M</td>
<td>82</td>
<td>14</td>
<td>31</td>
</tr>
<tr>
<td>2</td>
<td>53</td>
<td>32</td>
<td>M</td>
<td>89</td>
<td>20</td>
<td>23</td>
</tr>
<tr>
<td>3</td>
<td>49</td>
<td>27</td>
<td>M</td>
<td>90</td>
<td>11</td>
<td>41</td>
</tr>
<tr>
<td>4</td>
<td>70</td>
<td>18</td>
<td>M</td>
<td>74</td>
<td>17</td>
<td>40</td>
</tr>
<tr>
<td>5</td>
<td>68</td>
<td>29</td>
<td>M</td>
<td>83</td>
<td>12</td>
<td>39</td>
</tr>
<tr>
<td>6</td>
<td>29</td>
<td>21</td>
<td>M</td>
<td>87</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>49</td>
<td>30</td>
<td>M</td>
<td>84</td>
<td>22</td>
<td>31</td>
</tr>
<tr>
<td>8</td>
<td>44</td>
<td>21</td>
<td>F</td>
<td>86</td>
<td>15</td>
<td>13</td>
</tr>
<tr>
<td>9</td>
<td>42</td>
<td>31</td>
<td>M</td>
<td>87</td>
<td>29</td>
<td>40</td>
</tr>
<tr>
<td>10</td>
<td>48</td>
<td>21</td>
<td>M</td>
<td>90</td>
<td>14</td>
<td>16</td>
</tr>
</tbody>
</table>

Mean 47.8 26.2 85.2 15.9 27.6

SEM 4.5 1.7 1.5 2.1 4.3

BMI: body mass index; RDI: respiratory disturbance (apnoea + hypopnoea) index; M: male; F: female; $SpO_2$: arterial oxygen saturation; REM: rapid eye movement.
the average and minimum values of SpO2 for each (man-
ually scored) sleep stage.

Sleep recordings were scored blind by a single observer. 
Sleep scoring (20 s epochs) was performed according to
the criteria of RECHTSCHAFFEN and KALES [13]. Hypopnoea
was defined as a 50% or greater decrease from baseline
in abdominal and thoracic excursions and/or airflow
lasting for 10 s or more. Apnoea was defined as cessation
of air flow for 10 s or more and characterized as
obstructive, mixed or central. Sleep-disordered breathing
was quantitated by calculating apnoea index (AI; apnoeas-h-1 of sleep), respiratory disturbance index (RDI, apnoeas plus hypopnoeas-h-1 of sleep) and O2 saturation
(nadir and average).

Statistics

The paired Student’s t-test was used to compare mean
data for placebo and baclofen nights. The Chi-squared
test was used to examine the difference in the relative
prevalence of various types of apnoea between placebo
and baclofen nights. The p-values reported are based
on a two-tailed test; a p-value below 0.05 was consid-
ered statistically significant. Results are expressed as
means±SEM.

Results

Sleep architecture data are presented in table 2. Total
sleep time (TST) was increased significantly with baclofen
treatment. Rapid eye movement (REM) sleep increased
as a percentage of TST, as well as in absolute duration.
The duration of nonREM sleep, but not slow-wave sleep
(i.e. Stages 3 and 4), also increased slightly. The increase
in TST was due equally to an increase in duration of
REM sleep and of Stages 1 and 2 nonREM. Time awake
after sleep onset was decreased after baclofen. No sig-
nificant differences occurred on the baclofen night in the
frequency of arousals, sleep efficiency, sleep latency, or
the time available for sleep (lights out time).

A consequence of the randomization was that seven
patients received baclofen on the second night of the
study and only three received it on the first study night.
Since significant differences were shown in a number of
key sleep variables between baclofen and placebo nights
and sleep efficiency may improve in sequential night
sleep studies, a separate analysis looking for an order

Table 2. – The effect of baclofen on sleep architecture

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Baclofen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total sleep time min</td>
<td>356±9.9</td>
<td>386±9.9***</td>
</tr>
<tr>
<td>Lights out time min</td>
<td>424±10.2</td>
<td>442±8.0</td>
</tr>
<tr>
<td>Sleep onset latency min</td>
<td>6.3±1.7</td>
<td>8.5±2.2</td>
</tr>
<tr>
<td>Time awake after sleep onset min</td>
<td>71±10.3</td>
<td>51±7.9*</td>
</tr>
<tr>
<td>NonREM duration min</td>
<td>295±6.8</td>
<td>311±8.9*</td>
</tr>
<tr>
<td>NonREM % Total sleep time</td>
<td>83±1.8</td>
<td>81.5±2.1*</td>
</tr>
<tr>
<td>Stages 1 and 2 duration min</td>
<td>55±9.9</td>
<td>51±8.9</td>
</tr>
<tr>
<td>Stages 3 and 4 duration min</td>
<td>55±9.9</td>
<td>51±8.9</td>
</tr>
<tr>
<td>REM duration min</td>
<td>61±7.5</td>
<td>76±9.0**</td>
</tr>
<tr>
<td>REM % Total sleep time</td>
<td>17±1.8</td>
<td>20±2.1*</td>
</tr>
<tr>
<td>REM latency min</td>
<td>79±16.2</td>
<td>97±19.8</td>
</tr>
</tbody>
</table>

Values shown are mean±SEM. REM: rapid eye movement; NS: nonsignificant. *, **, ***: p<0.05, 0.02, 0.001, two-tailed paired t-test.

effect was undertaken. No order effect could be shown
for any of the sleep variables; however, such an effect
can not be entirely excluded because of the small study
population.

Data on sleep-disordered breathing are presented in
Table 3. Mean pulse oximetry oxygen saturation (SpO2)
for total sleep was significantly reduced after baclofen,
and for nonREM the difference approached statistical
significance. There were no statistically significant dif-
fferences in RDI, or minimum SpO2 following baclofen,
although there was a trend toward an increase in RDI
and a decrease in minimum SpO2 in nonREM sleep.
Apnoea index was low and did not differ between the
study nights (placebo 1.4±0.5 apnoea-h-1; baclofen 3.8±2.0
apnoea-h-1; NS). No change in the ratio of the various
apnoea types was observed after baclofen (obstructive:
mixed: central apnoeas: placebo 1:0.1:0.6; baclofen 1:0.5:
0.5; NS). Apnoea and hypopnoea durations did not dif-
fer on the study nights (mean apnoea+hypopnoea dura-
tion: placebo 16.2±1.3 s; baclofen 16.6±1.2 s; NS).

Discussion

The findings of this study were that a standard dose
of baclofen, administered at night to snorers with mild
sleep-disordered breathing, altered sleep architecture and

Table 3. – The effect of baclofen on sleep disordered breathing

<table>
<thead>
<tr>
<th></th>
<th>Total sleep</th>
<th>nonREM</th>
<th>REM</th>
</tr>
</thead>
<tbody>
<tr>
<td>RDI events-h-1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SpO2 % mean</td>
<td>95.2±4.0</td>
<td>87.6±2.1</td>
<td>87.6±2.1</td>
</tr>
<tr>
<td>SpO2 % min</td>
<td>7.1±1.3</td>
<td>95.3±0.5</td>
<td>88.7±2.0</td>
</tr>
<tr>
<td>RDI events-h-1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SpO2 % mean</td>
<td>95.3±0.5</td>
<td>88.7±2.0</td>
<td>15.8±4.1</td>
</tr>
<tr>
<td>SpO2 % min</td>
<td>7.1±1.3</td>
<td>95.3±0.5</td>
<td>88.7±2.0</td>
</tr>
<tr>
<td>p-value*</td>
<td>0.161 (ns)</td>
<td>0.032</td>
<td>0.137 (ns)</td>
</tr>
</tbody>
</table>

Data are presented as mean±SEM. SpO2: pulse oximetry oxygen saturation. For further abbreviations see legends to tables 1 and 2. *: two-tailed paired t-test.
produced a minor decrease in oxygen saturation during sleep, without an increase in sleep apnoeas or hypopnoeas. Baclofen appeared to have a sedative effect. Total sleep time, duration of REM and nonREM sleep, and the proportion of sleep spent in nonREM were increased. The increase in nonREM sleep was due to an increase in duration of Stages 1 and 2 and not Stages 3 and 4 (delta sleep). Time awake after sleep onset was reduced by 28%. These findings are in agreement with those of a recent study of patients with periodic limb movements in sleep, in which 20 mg of baclofen increased the duration of total sleep and REM sleep but did not change the amount of delta sleep [2].

Baclofen produced a small but significant reduction in mean SpO2 during sleep. Because the total time spent in apnoea/hypopnoea was very short compared with total sleep time and because there was no significant increase in disordered breathing events following baclofen, it can be inferred that the reduction in mean SpO2 resulted from a reduction in baseline sleep SpO2. The most likely explanation for this reduction is a fall in resting ventilation. GABA has been shown to decrease ventilation and ventilatory responsiveness to CO2 in the rat [3], and to have a similar ventilatory depressant effect in the dog [4] and cat [5].

There was no significant increase in the frequency of disordered breathing events for sleep overall, or for either REM or nonREM sleep. However, it is known that there is considerable night-to-night variability in RDI in patients with mild sleep-disordered breathing [14], such as those enrolled in the present study. The question arises, therefore, as to whether or not there was sufficient statistical power in our study to detect an important difference in sleep-disordered breathing after baclofen, had such a change occurred. The night-to-night coefficient of variation in RDI (diagnostic vs placebo study nights) was relatively high (33%), as expected. However, we calculated [15] that given this variance and our sample size of 10 we would have been able to detect a real difference in RDI of 48% or greater (study power of 90% and two-tailed significance level of 0.05). That is, in the present study, we should have been able to detect a real increase in mean RDI from say 9 (the approximate mean RDI on placebo night) to 13.5. We argue that a change in mean RDI of less than this would not be clinically important in such a population, and, therefore, that our study had sufficient statistical power to detect meaningful changes in sleep-disordered breathing after baclofen, had such changes been present.

Apnoea and hypopnoea duration was not increased following baclofen in our study. Since most disordered breathing events during sleep are terminated by an arousal in sleep, this implies that sedation from 25 mg of baclofen is not sufficient to increase arousal threshold.

We know of no other study of the effects of baclofen on sleep-disordered breathing. However, both alcohol and benzodiazepines, which exert their effects at least in part through GABA-ergic pathways [16–18], have been shown to increase sleep-disordered breathing in susceptible populations [19–21].

It is possible that clinically significant increases in sleep-disordered breathing may be observed in patients who have a greater underlying tendency to sleep-disordered breathing, patients given higher doses of baclofen, or patients on chronic treatment. Changes in sleep architecture at higher doses, however, would not necessarily predispose to more sleep-disordered breathing. Firstly, a decrease in the amount of REM sleep at high dosage, as shown elsewhere [2], would tend to mitigate against a worsening of apnoea. Secondly, whilst slow-wave sleep is increased at high doses of baclofen [2], studies with gamma hydroxybutyrate, a GABA metabolite known to also promote slow-wave sleep, failed to alter RDI in patients with OSA [22].

Baclofen is widely used in patients with neurological disorders, such as multiple sclerosis and spinal cord injuries, to treat painful muscle spasms. A number of such patients have altered upper airway or respiratory function as a result of the neurological disease, and are, therefore, prone to sleep-disordered breathing. Our data suggest that baclofen administration in such patients is safe if underlying sleep-disordered breathing is mild. We and other investigators [7–10] have previously shown that quadriplegic patients are prone to sleep apnoea and moderately severe episodic oxygen desaturation in sleep. The results of the present study suggest that baclofen administration alone is unlikely to be the explanation for these observations.

In conclusion, a small dose of the GABA agonist baclofen at night has been shown to increase total sleep time, prolong REM sleep and Stages 1 and 2 nonREM sleep, and reduce the time spent awake after sleep onset. Baclofen decreased mean nocturnal oxygen saturation slightly, but had no significant effect on the frequency of sleep-disordered breathing events in a susceptible population of snorers.

References

7. Flavell H, Marshall R, Thornton AT, Clements PL, Antic R, McEvoy RD. Hypoxia episodes during sleep...


17. Allan AM, Burnett D, Harris RA. Ethanol-induced changes in chloride flux are mediated by both GABA (A) and GABA (B) receptors. Alcohol Clin Exp Res 1991; 15(2): 233–237.


